GSK
GSK
GSK (GSK) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citigroup | Maintained | Neutral | — | Jul 24, 2026 |
| Barclays | Downgraded | Equal-Weight → Underweight | — | Jan 6, 2026 |
| Jefferies | Initiated Coverage | Hold → Buy | — | Oct 27, 2025 |
| Jefferies | Downgraded | Buy → Hold | — | Nov 12, 2024 |
| Guggenheim | Downgraded | Buy → Neutral | — | Oct 31, 2024 |
| UBS | Downgraded | Buy → Neutral | — | Jul 8, 2024 |
| Jefferies | Maintained | Buy | $53.00 from $52.50 | Jul 2, 2024 |
| Goldman Sachs | Initiated Coverage | Neutral | $47.00 | May 30, 2024 |
| Guggenheim | Upgraded | Neutral → Buy | — | Mar 4, 2024 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $44.00 | Jan 23, 2024 |
| Jefferies | Upgraded | Hold → Buy | $48.00 from $38.50 | Jan 3, 2024 |
Frequently asked questions
What is the latest analyst rating on GSK?
On Jul 24, 2026, Citigroup maintained GSK at Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.